Omega Therapeutics advances epigenomic programming platform

By The Science Advisory Board staff writers

July 29, 2020 -- Omega Therapeutics has received $85 million in financing to support clinical trials of its epigenomic controllers for programs in oncology, inflammation, autoimmune, metabolic, and rare genetic diseases.

The company's epigenomic programming platform selectively directs the human genome to treat and cure disease by precisely controlling genomic expression without altering native nucleic acid sequences. The platform modulates insulated genomic domains to up- or down-regulate single or multiple genes simultaneously.

The company calls the genomic modulators "epigenomic controllers," and said they are engineered to precisely tune genomic activity with high target specificity and durability. They are composed of a DNA-binding domain and an epigenetic effector domain delivered as messenger RNA which modulate gene expression, according to the firm.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here